ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - abatacept - אבקה להכנת תמיסה מרוכזת לעירוי - abatacept 250 mg - abatacept - abatacept - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease modifying anti rheumatic drugs (dmards) including methotrexate (mtx) or a tnf-alpha inhibitor.a reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate.polyarticular juvenile idiopathic arthritis:orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (jia) in paediatric patients 6 years of age and older who have had an insufficient response to other dmards including at least one tnf inhibitor. orencia has not been studied in children under 6 years old.

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - abatacept - תמיסה להזרקה - abatacept 125 mg/ml - abatacept - abatacept - orencia is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (dmards) other than tumor necrosis factor (tnf) antagonists.

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - adalimumab - תמיסה להזרקה - adalimumab 100 mg / 1 ml - adalimumab

ישראל - עברית - Ministry of Health

neopharm ltd, israel - certolizumab pegol - תמיסה להזרקה - certolizumab pegol 200 mg/ml - certolizumab pegol

ישראל - עברית - Ministry of Health

novartis israel ltd - adalimumab - תמיסה להזרקה - adalimumab 50 mg/ml - adalimumab

ישראל - עברית - Ministry of Health

neopharm (israel)1996 ltd - adalimumab - תמיסה להזרקה - adalimumab 50 mg/ml - adalimumab

ישראל - עברית - Ministry of Health

amgen europe b.v. - adalimumab - תמיסה להזרקה - adalimumab 50 mg / 1 ml - adalimumab

ישראל - עברית - Ministry of Health

padagis israel agencies ltd, israel - infliximab - תמיסה להזרקה - infliximab 120 mg/ml - infliximab

ישראל - עברית - Ministry of Health

padagis israel agencies ltd, israel - adalimumab - תמיסה להזרקה - adalimumab 100 mg/ml - adalimumab

ישראל - עברית - Ministry of Health

teva israel ltd - glatiramer acetate - תמיסה להזרקה - glatiramer acetate 20 mg/ml - glatiramer acetate - glatiramer acetate - for reducing the frequency of relapses in pateints with relapsing-remitting multiple sclerosis. copaxone is indicated for the treatment of patients who have experienced a well defined first clinical episode and are determined to be at high risk of developing clinically definite multiple sclerosis (cdms). these patients should have mri findings which are compatible with the diagnosis of multiple sclerosis.